REVIEW Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibit ABCA1-mediated cellular lipid efflux.
REFERENCES
[1]
Neuworth, Martin B. Anticholesteremic 2,2-bis(3,5-dialkyl-4-hydroxyphenylthio)alkanes Fr. (1969), FR 1561853 A 19690328.
[2]
Neuworth, Martin B.; Laufer, Rohert J.; Barnhart, James W.; Sefranka, J. A.; McIntosh, D. D. Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols Journal of Medicinal Chemistry (1970), 13(4), 722-5.
[3]
Pfuetze K D; Dujovne C A Probucol Current atherosclerosis reports (2000), 2(1), 47-57.
[4]
Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GHProbucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2345-50. Epub 2004 Oct 28.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.